clinical trial tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo- controlled, phase 3 Tirzepatide for the Maintenance of

When considered against active comparators, semaglutide also increased the likelihood of participants losing 5% fasting body weight, with ORs ranging from 1.29 (95% CI 0.70, 2.13 [T2DM]) to 2.17 (95% CI 1.44, 3.27 [NGT]) with liraglutide 3.0 mg and from 6.09 (95% CI 2.86, 11.95 [total population]) to 7.75 (95% CI 5.29, 11.37 [non-T2DM]) with orlistat 120 mg three times daily (TID)

If raw price is your priority, also see our cheapest online GLP-1 programs breakdown

The influence of the gut microbiome on obesity, metabolic syndrome and gastrointestinal disease

Mediterranean diet and cardiovascular risk factors: a systematic review